Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

Phase 4 Unknown 85 enrolled Health Sciences North Research Institute UConn Health · collab

RandomizedFactorialDouble-blindPrevention

Summary

This 5-year proposal is a randomized study of split-virus influenza vaccine (SVV) in a high-dose (HD) vs. standard-dose (SD) formulation in each of five influenza seasons to define the key determinants of vaccine-mediated protection against influenza and how these immunologic mediators may be enhanced by vaccination with a newly approved high-dose influenza vaccine in older people

Timeline

Start: 2014-10
Primary completion: 2019-12
Completion: 2019-12

Publications

McElhaney JE, Verschoor CP, Haynes L, Pawelec G, Loeb M, Andrew MK, Kuchel GA. Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults. Front Aging. 2021 May;2:649110. doi: 10.3389/fragi.2021.649110. Epub 2021 May 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Influenza Virus Vaccine	Vaccine	—	—

Indications

No indication recorded.